Ann: Interim data from MSKCC study, page-5

This is only a phase 1 trial to test safety, maximum tolerated dose and we are seeing a 100% response. This is amazingly positive for paxalisib as a platform drug and as a combination therapy. I don't care for MR market because the data doesn't lie. I predict another out-licensing deal before December.

We are living in strange times where money isn't money anymore, it's just 1 and 0. The data doesn't lie. The trials are progressing.